Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases
- 61 Downloads
Background and Objective
To clarify whether there are different expressions between lung cancer and benign pulmonary diseases, we studied seven microRNAs (miRNAs) in serum from patients with non-small cell lung cancer (NSCLC), benign pulmonary nodules and four pulmonary inflammation diseases.
We detected the expression of miRNAs using quantitative reverse transcriptase–polymerase chain reaction (qRT–PCR).
We found that five miRNA ratios—miR-15b-5p/miR-146b-3p, miR-20a-5p/miR-146b-3p, miR-19a-3p/miR-146b-3p, miR-92a-3p/miR-146b-3p, and miR-16-5p/miR-146b-3p—show higher expression in the NSCLC group than the benign pulmonary nodule group, and 13 ratios of miRNAs were significantly upregulated in the NSCLC group compared with the pulmonary inflammation diseases group. Receiver operating characteristic (ROC) curve analysis was performed. For NSCLC and benign pulmonary nodules, the sensitivity and specificity were 0.70 and 0.90, respectively. For NSCLC and pulmonary inflammation diseases, the sensitivity and specificity were 0.81 and 0.71, respectively.
The ratios of miRNAs can be used as potential non-invasive biomarkers for diagnosis of early-stage NSCLC and benign pulmonary diseases.
Compliance with Ethical Standards
Conflict of interest
All authors (LF, JS, JT, DL, CW, QX, HC, BS and HQ) declare that they have no conflicts of interest.
This study was funded by the Fundamental Research Funds for the Central Universities (no. 20153590) and the Chinese National Natural Science Foundation (nos. 81703847, 81473469).
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 2.Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) [based on November 2011 SEER data submission, posted to the SEER website April 2012]. Bethesda: National Cancer Institute; 2012. https://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 1 May 2017.
- 8.Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014;32(8):768–73. https://doi.org/10.1200/jco.2013.50.4357.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Kahn N, Kuner R, Eberhardt R, Meister M, Muley T, Winteroll S, et al. Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. J Thorac Cardiovasc Surg. 2009;138(2):474–9. https://doi.org/10.1016/j.jtcvs.2009.04.024.CrossRefPubMedGoogle Scholar
- 22.Welch HG, Woloshin S, Schwartz LM, Gordis L, Gotzsche PC, Harris R, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med. 2007;167(21):2289–95. https://doi.org/10.1001/archinte.167.21.2289.CrossRefPubMedGoogle Scholar
- 26.Van Pottelberge GR, Mestdagh P, Bracke KR, Thas O, van Durme YM, Joos GF, et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(7):898–906. https://doi.org/10.1164/rccm.201002-0304OC.CrossRefPubMedGoogle Scholar
- 34.Molina-Pinelo S, Suarez R, Pastor MD, Nogal A, Marquez-Martin E, Martin-Juan J, et al. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers. 2012;32(4):221–30. https://doi.org/10.3233/DMA-2011-0882.CrossRefPubMedPubMedCentralGoogle Scholar